Xiamen Amoytop Biotech Co Ltd banner
X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 57.46 CNY -3.18% Market Closed
Market Cap: ¥23.5B

EV/GP

6.6
Current
39%
Cheaper
vs 3-y average of 10.7

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
6.6
=
Enterprise Value
¥25.7B
/
Gross Profit
¥3.4B

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
6.6
=
Enterprise Value
¥25.7B
/
Gross Profit
¥3.4B

Valuation Scenarios

Xiamen Amoytop Biotech Co Ltd is trading below its 3-year average

If EV/GP returns to its 3-Year Average (10.7), the stock would be worth ¥93.61 (63% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+109%
Average Upside
87%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 6.6 ¥57.46
0%
3-Year Average 10.7 ¥93.61
+63%
5-Year Average 11.2 ¥97.43
+70%
Industry Average 13.8 ¥120.13
+109%
Country Average 13.6 ¥118.25
+106%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
CN
Xiamen Amoytop Biotech Co Ltd
SSE:688278
24.2B CNY 6.6 22.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 0 -160 127.7
US
Abbvie Inc
NYSE:ABBV
373.6B USD 9.8 89.2
US
Amgen Inc
NASDAQ:AMGN
182.2B USD 7.5 24.2
US
Gilead Sciences Inc
NASDAQ:GILD
159.9B USD 7.5 19.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 769.8 -533.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
107.5B USD 9.7 27.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.5B USD 4.3 16.6
NL
argenx SE
XBRU:ARGX
41.3B EUR 11.9 37.4
US
Seagen Inc
F:SGT
39.3B EUR 26 -61.8
AU
CSL Ltd
ASX:CSL
60.6B AUD 6.4 29.4
P/E Multiple
Earnings Growth PEG
CN
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Average P/E: 33.3
22.7
27%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
89.2
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.2
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
19.1
16%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.5
19%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
14%
1.2
NL
argenx SE
XBRU:ARGX
37.4
30%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
AU
CSL Ltd
ASX:CSL
29.4
9%
3.3

Market Distribution

Lower than 76% of companies in China
Percentile
24th
Based on 6 967 companies
24th percentile
6.6
Low
0 — 8
Typical Range
8 — 23.3
High
23.3 —
Distribution Statistics
China
Min 0
30th Percentile 8
Median 13.6
70th Percentile 23.3
Max 17 898 541.1

Xiamen Amoytop Biotech Co Ltd
Glance View

Market Cap
23.5B CNY
Industry
Biotechnology

Xiamen Amoytop Biotech Co., Ltd., nestled in the heart of China's coastal city Xiamen, unfolds its narrative as a dynamic player in the biotechnology and healthcare industries. Born from an environment brimming with innovation, the company has diligently carved its niche by focusing on the research, development, and commercialization of diagnostic reagents and test kits. Its core competency lies in crafting solutions designed for precision and reliability, addressing the ever-evolving needs of laboratories and healthcare providers. Through a blend of cutting-edge technology and a keen understanding of biological complexities, Xiamen Amoytop has established itself as a reliable partner, providing essential tools that drive accurate diagnostics and improve patient outcomes across the globe. The company generates revenue by designing and delivering an extensive array of diagnostic products that are indispensable to modern medical practices. From infectious disease diagnostics to blood-based tests, Xiamen Amoytop leverages advancements in molecular biology to offer products that elevate the standards of health diagnostics. By supplying these critical products, the company ensures a steady flow of income sourced from healthcare facilities, research institutions, and diagnostic laboratories both domestically and internationally. Through its robust distribution network and focus on quality assurance, the company continues to expand its market presence, translating its technological prowess into financial growth and global impact.

Intrinsic Value
86.81 CNY
Undervaluation 34%
Intrinsic Value
Price ¥57.46
X
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett